Galectin-1 is an independent prognostic factor for local recurrence and survival after definitive radiation therapy for patients with squamous cell carcinoma of the uterine cervix

International Journal of Radiation Oncology Biology Physics

Volumn 87, Issue 5, 2013, Pages 975-982

  Huang, Eng Yen ^a   Chanchien, Chan Chao ^a   Lin, Hao ^a   Wang, Chung Chi ^a   Wang, Chong Jong ^a   Huang, Chao Cheng ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; DRUG PRODUCTS; HAZARDS; MULTIVARIANT ANALYSIS; TISSUE ENGINEERING; TUMORS;

AREAS UNDER THE CURVES; COX PROPORTIONAL HAZARD MODEL; IMMUNOHISTOCHEMISTRY; INTERNATIONAL FEDERATION; KAPLAN-MEIER METHOD; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; SQUAMOUS CELL CARCINOMA;

RADIOTHERAPY;

CARCINOEMBRYONIC ANTIGEN; GALECTIN 1; HEMOGLOBIN; TUMOR MARKER;

ADULT; AGED; BRACHYTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONFIDENCE INTERVAL; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HAZARD RATIO; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PELVIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA; UNIVARIATE ANALYSIS; UTERINE CERVIX CARCINOMA; AREA UNDER THE CURVE; CARCINOMA, SQUAMOUS CELL; CHEMISTRY; EXTRACELLULAR MATRIX; MORTALITY; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; SECONDARY; SURVIVAL RATE; TUMOR RECURRENCE; UTERINE CERVICAL NEOPLASMS;

AGED; AREA UNDER CURVE; CARCINOMA, SQUAMOUS CELL; CONFIDENCE INTERVALS; EXTRACELLULAR MATRIX; FEMALE; GALECTIN 1; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIATION TOLERANCE; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84888288249     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.08.037     Document Type: Article

References (52)

1. E.Y. Huang, H.C. Hsu, and L.M. Sun Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix Int J Radiat Oncol Biol Phys 81 2011 1105 1113
2. T.J. Kim, J.W. Lee, and S.Y. Song Increased expression of pAKT is associated with radiation resistance in cervical cancer Br J Cancer 94 2006 1678 1682
3. N. Chaudary, M. Pintilie, and D. Hedley Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation Cancer 118 2012 3105 3115
4. M.G. Noordhuis, J.J. Eijsink, and F. Roossink Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: A systematic review Int J Radiat Oncol Biol Phys 79 2011 325 334
5. M. Hockel, K. Schlenger, and B. Aral Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix Cancer Res 56 1996 4509 4515
6. E.K. Rofstad, K. Sundfør, and H. Lyng Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis Br J Cancer 83 2000 354 359
7. L.B. Harrison, M. Chadha, and R.J. Hill Impact of tumor hypoxia and anemia on radiation therapy outcomes Oncologist 7 2002 492 508
8. P. Vaupel, O. Thews, and A. Mayer Oxygenation status of gynecologic tumors: What is the optimal hemoglobin level? Strahlenther Onkol 178 2002 727 731
9. R.S. Bush, R.D. Jenkin, and W.E. Allt Definitive evidence for hypoxic cells influencing cure in cancer therapy Br J Cancer 3 1978 302 306
10. J. Dunst, T. Kuhnt, and H.G. Strauss Anemia in cervical cancers: Impact on survival, patterns of relapse, and association with hypoxia and angiogenesis Int J Radiat Oncol Biol Phys 56 2003 778 787
11. P. Burri, V. Djonov, and D.M. Aebersold Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy Int J Radiat Oncol Biol Phys 56 2003 494 501
12. K. Dellas, M. Bache, and S.U. Pigorsch Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer Strahlenther Onkol 184 2008 169 174
13. W.G. McKenna, M.C. Weiss, and B. Endlich Synergistic effect of the v-myc oncogene with H-ras on radioresistance Cancer Res 50 1990 97 102
14. W.G. McKenna, M.C. Weiss, and V.J. Bakanauskas The role of the H-ras oncogene in radiation resistance and metastasis Int J Radiat Oncol Biol Phys 18 1990 849 859
15. A.F. Hermens, and P.A. Bentvelzen Influence of the H-ras oncogene on radiation responses of a rat rhabdomyosarcoma cell line Cancer Res 52 1992 3073 3082
16. I.N. Mammas, A. Zafiropoulos, and E. Koumantakis Transcriptional activation of H- and N-ras oncogenes in human cervical cancer Gynecol Oncol 92 2004 941 948
17. J.H. Lee, S.K. Lee, and M.H. Yang Expression and mutation of H-ras in uterine cervical cancer Gynecol Oncol 62 1996 49 54
18. Q.T. Le, C. Kong, and P.W. Lavori Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas Int J Radiat Oncol Biol Phys 69 2007 167 175
19. X.Y. Zhao, T.T. Chen, and L. Xia Hypoxia inducible factor-1 mediates expression of galectin-1: The potential role in migration/invasion of colorectal cancer cells Carcinogenesis 31 2010 1367 1375
20. Q.T. Le, G. Shi, and H. Cao Galectin-1: A link between tumor hypoxia and tumor immune privilege J Clin Oncol 23 2005 8932 8941
21. A. Paz, R. Haklai, and G. Elad-Sfadia Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation Oncogene 20 2001 7486 7493
22. G. Elad-Sfadia, R. Haklai, and E. Ballan Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase J Biol Chem 277 2002 37169 37175
23. C. Chen, N. Pore, and A. Behrooz Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia J Biol Chem 276 2001 9519 9525
24. X.Y. Zhao, K.W. Zhao, and Y. Jiang Synergistic induction of galectin-1 by CCAAT/enhancer binding protein alpha and hypoxia-inducible factor 1alpha and its role in differentiation of acute myeloid leukemic cells J Biol Chem 286 2011 36808 36819
25. E.Y. Huang, Y.F. Chen, and Y.M. Chen A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells Cell Death Dis 3 2012 e251
26. A.N. Viswanathan, S. Beriwal, and J.F. De Los Santos The American Brachytherapy Society treatment recommendations for locally advanced carcinoma of the cervix part II: High dose-rate brachytherapy Brachytherapy 11 2012 47 52
27. T. Toita, Y. Kakinohana, and K. Ogawa Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: Analysis of dose and fractionation schedule Int J Radiat Oncol Biol Phys 56 2003 1344 1353
28. L.M. McShane, D.G. Altman, and W. Sauerbrei Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics Reporting recommendations for tumor marker prognostic studies J Clin Oncol 20 2005 9067 9072
29. C.J. Wang, E.Y. Huang, and L.M. Sun Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer Int J Radiat Oncol Biol Phys 59 2004 179 189
30. N. Kohrenhagen, H.U. Volker, and M. Kapp Increased expression of galectin-1 during the progression of cervical neoplasia Int J Gynecol Cancer 16 2006 2018 2022
31. H.J. Kim, I.G. Do, and H.K. Jeon Galectin 1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer Hum Pathol 44 2013 62 68
32. F.A. van den Brûle, D. Waltregny, and V. Castronovo Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients J Pathol 193 2001 80 87
33. H.J. Kim, H.K. Jeon, and Y.J. Cho High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion Eur J Cancer 48 2012 1914 1921
34. Y. Seo, S.Y. Yoo, and M.S. Kim Nomogram prediction of overall survival after curative irradiation for uterine cervical cancer Int J Radiat Oncol Biol Phys 79 2011 782 787
35. J.H. Hong, C.S. Tsai, and J.T. Chang The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy Int J Radiat Oncol Biol Phys 41 1998 823 830
36. C.A. Perez, P.W. Grigsby, and H. Castro-Vita Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy Int J Radiat Oncol Biol Phys 32 1995 1275 1288
37. J.H. Hong, M.S. Chen, and F.J. Lin Prognostic assessment of tumor regression after external irradiation for cervical cancer Int J Radiat Oncol Biol Phys 22 1992 913 917
38. M.G. Noordhuis, J.J. Eijsink, and K.A. Ten Hoor Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo) radiation and survival in cervical cancer Clin Cancer Res 15 2009 7389 7397
39. J. Pérez-Regadera, A. Sánchez-Muñoz, and J. De-la-Cruz Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer Oncology 76 2009 133 141
40. H. Ishikawa, H. Sakurai, and M. Hasegawa Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma Int J Radiat Oncol Biol Phys 60 2004 513 521
41. G.J. Hutchison, H.R. Valentine, and J.A. Loncaster Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: Correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix Clin Cancer Res 10 2004 8405 8412
42. R.P. Dings, B.W. Williams, and C.W. Song Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells Int J Cancer 115 2005 312 319
43. V.L. Thijssen, R. Postel, and R.J. Brandwijk Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy Proc Natl Acad Sci U S A 103 2006 15975 15980
44. D.J. Laderach, L.D. Gentilini, and L. Giribaldi A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease Cancer Res 73 2013 86 96
45. S. Rorive, N. Belot, and C. Decaestecker Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma Glia 33 2001 241 255
46. V. Mathieu, E.M. de Lassalle, and J. Toelen Galectin-1 in melanoma biology and related neo-angiogenesis processes J Invest Dermatol 132 2012 2245 2254
47. M.K. Gandhi, G. Moll, and C. Smith Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma Blood 110 2007 1326 1329
48. P. Kamper, M. Ludvigsen, and K. Bendix Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractorydisease in classical Hodgkin lymphoma Blood 117 2011 6638 6649
49. S.J. Rodig, J. Ouyang, and P. Juszczynski AP1-dependent galectin-1 expression delineates classical Hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features Clin Cancer Res 14 2008 3338 3344
50. F. van den Brûle, S. Califice, and F. Garnier Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin Lab Invest 83 2003 377 386
51. C. Vale, J.F. Tierney, and L.A. Stewart Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data from 18 randomized trials J Clin Oncol 26 2008 5802 5812
52. P.G. Rose, B.N. Bundy, and E.B. Watkins Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer N Engl J Med 340 1999 1144 1153